Description:
A drug used with fulvestrant to treat adults with hormone-receptor positive, HER2-negative breast cancer that has spread and has an abnormal PIK3CA, AKT1, or PTEN gene. It is used in patients whose cancer came back or got worse during or after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Capivasertib blocks a protein called AKT, which is involved in cell signaling, cell growth, and cell survival. Blocking this protein may help keep cancer cells from growing and may kill them. Capivasertib is a type of kinase inhibitor. Also called Truqap.
